Skip to content
StockMarketAgent
Direct answer
ELV trades against a final fair-value range of $411.38-$853.64, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $411, high $854, with mid-point at $632.
Stock analysis

ELV ELV fair value $411–$854

ELV
By StockMarketAgent.AI team· supervised by
विश्लेषित: 2026-05-13अगला अद्यतन: 2026-08-13Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
मूल्य
$381.75
▲ +250.57 (+65.64%)
उचित मूल्य
$632
$411–$854
रेटिंग
मज़बूत ख़रीद
confidence 77/100
ऊपरी अंतर
+65.6%
upside to fair value
सुरक्षा मार्जिन
$537.47
MoS level · 15%
बाज़ार पूंजीकरण
$82.9B
P/E fwd 13.1
अंग्रेज़ी फ़ॉलबैकHI
अनुवाद होने तक अंग्रेज़ी स्रोत दिखा रहा है
इस रिपोर्ट का अभी अनुवाद नहीं हुआ है। अनुवाद कतार पकड़ने पर कुछ मिनट में रिफ़्रेश करें।

§1 कार्यकारी सारांश

  • Composite fair value $632 with high case $854.
  • Implied upside of 65.6% to fair value.
  • Moat 9/10 · confidence 77/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$632
Margin of safety
+39.6%
Confidence
77/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$381.75Price
Low $411.38
Mid $632.32
High $853.64

ELV trades against a final fair-value range of $411.38-$853.64, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Scale advantages driven by a
    Scale advantages driven by a massive member base in Anthem.
  • Network effects within the integrated
    Network effects within the integrated Anthem and Carelon ecosystems.
  • Bull thesis
    Massive margin of safety with implied -6.18% perpetual growth at the current price.

§2 बेयर केस

A severe scenario where elevated MLR persists due to structural shifts in medical utilization, compounded by adverse Medicare rate changes, significantly compressing operating margins below their historical norms.

इस थीसिस के टूटने के तरीक़े

Unchecked Medical Cost Inflation

· Medium

Sustained elevated medical utilization drives MLR structurally higher, compressing operating margins permanently below historical averages.

FV impact
-35%
Trigger
12-24 Months

Severe Regulatory Reimbursement Cuts

· Low

Aggressive legislative action slashes Medicare Advantage and Medicaid reimbursement rates, effectively stunting top-line growth.

FV impact
-25%
Trigger
24-36 Months

Carelon Growth Stagnation

· Medium

Intense PBM competition limits Carelon's ability to win new external mandates, stalling the long-term margin-expansion thesis.

FV impact
-15%
Trigger
12-18 Months
निगरानी हेतु शीघ्र चेतावनी संकेत
मेट्रिकवर्तमानट्रिगर सीमा
Medical loss ratio sequentially rising above targeted corridors.MonitorDeterioration versus the report thesis
Regulatory announcements of tighter Medicare funding.MonitorDeterioration versus the report thesis
Stalling growth or mandate losses in the Carelon segment.MonitorDeterioration versus the report thesis
Operating margins dipping below the 5.0% normalized threshold.MonitorDeterioration versus the report thesis
Material reduction in projected share repurchase pacing.MonitorDeterioration versus the report thesis

§3 वित्तीय इतिहास

आय विवरण — पिछले छह कालखंड
लाइन आइटमT−0T−1T−2T−3T−4CAGR
अवधि2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
राजस्व$156.60B$171.34B$176.81B$199.13B+6.2%
सकल लाभ
परिचालन आय
शुद्ध आय$5.89B$5.99B$5.98B$5.66B-1.0%
EPS (डाइल्यूटेड)$24.81$25.22$25.68$25.21+0.4%
EBITDA
R&D
SG&A$15.91B$17.69B+2.7%

गुणवत्ता स्कोर

OCF / शुद्ध आय
0.76×
>1 उच्च आय गुणवत्ता दर्शाता है
लेखा गुणवत्ता गेट
Fail
सेक्टर-समायोजित गेट
ROIC
8.4%
निवेशित पूँजी पर प्रतिफल
खंड 3

Numbers analysis

नकद प्रवाह

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

पूँजी आवंटन

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

व्यक्तिगत सब्सक्राइबर — §4 आगे11 और खंड

पूरा विश्लेषण पढ़ें — 11 और खंड.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

हर कवर किए गए टिकर के लिए पूर्ण रिपोर्ट
रेटिंग संग्रह के 24 महीने
वॉचलिस्ट ब्रीफ़िंग और रेटिंग-परिवर्तन अलर्ट
किसी भी भाषा में PDF + DOCX निर्यात
मुफ़्त ट्रायल शुरू करें
कभी भी रद्द करें।
FAQ

ELV — frequently asked questions

  1. Based on our latest analysis, ELV looks meaningfully undervalued. The current price is $382 versus a composite fair-value midpoint of $632 (range $411–$854), which implies roughly 65.6% upside to the midpoint.
Related coverage

Names readers of ELV also follow

Same archetype: mature-compounder